WARS2-AS1

Across TCGA pan-cancer cohorts, WARS2-AS1 RNA is linked to patient survival in 25 of 34 cancer types, making it the most broadly survival-associated WARS2-AS1 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher WARS2-AS1 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated WARS2-AS1 expression acts as an unfavorable survival marker, although some lineages such as MESO and READ show a favorable association.

LIHC, LGG, and ACC are the cancer types where WARS2-AS1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Tertile	All	0.421	0.626	<.001	60	view →
LGG	DFS	Median	All	0.650	0.825	<.001	47	view →
ACC	DFS	Quartile	All	0.225	0.755	<.001	41	view →
MESO	OS	Median	II,III,IV	0.521	0.276	.001	37	view →
CESC	DFS	Quartile	All	0.630	0.812	.010	36	view →
READ	OS	Median	II,III,IV	0.971	0.850	.003	32	view →
KICH	DFS	Quartile	II,III,IV	0.323	0.928	<.001	28	view →
KIRP	DFS	Median	IV	0.037	0.527	.004	23	view →
THCA	OS	Quartile	II,III,IV	0.894	1.000	.005	21	view →
SKCM	DFS	Median	II,III,IV	0.478	0.696	.002	19	view →
UCS	OS	Median	II,III,IV	0.579	0.210	.006	16	view →
COAD	OS	Tertile	II,III,IV	0.770	0.888	.031	11	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 25 lineages.

WARS2-AS1–LIHC (DFS)

Open the LIHC breakdown →